Shattuck is developing a breakthrough platform for immunotherapy, which harnesses the human immune system to improve outcomes for patients battling cancer and inflammatory disease. Shattuck's proprietary technology represents the next evolutionary step in cancer therapy by endowing one molecule with multiple, synergistic functions.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 06/15/20 | $118,000,000 | Series B |
Avidity Partners EcoR1 Capital Emerson Collective Fidelity Management & Research Company Hatteras Venture Partners Janus Henderson Investors Partner Fund Management Piper Sandler & Co. Redmile Group  | undisclosed |
